Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1990 Nov;30(6):331–341. doi: 10.1007/BF01786882

Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide

Margaret Nelson 1,✉, David Nelson 1
PMCID: PMC11038617  PMID: 2302724

Abstract

Tumor cells of all types and species tested have been found to produce, in culture, substances that depress the expression of cell-mediated immunity, in the form of delayed-type hypersensitivity reactions in mouse feet. The factors responsible appear related immunologically to the retroviral envelope protein p15E. We have measured the effects of tumor products and conjugates of a p15E-related peptide, CKS-17, on interleukin-2 (IL-2) production by cultured, mitogen-stimulated EL4 cells; in this system IL-2 production is independent of IL-1. Supernatants of cultures of mouse, human and guinea-pig tumor cells inhibited IL-2 production in a dose-dependent fashion. CKS-17 conjugates, but not control conjugates, also inhibited IL-2 production. Responses to IL-2 of the CTLL line used were less inhibited by tumor products and very slightly inhibited by CKS-17 conjugates. IL-2 receptor density, assayed by flow cytometry, was not inhibited. IL-2 production was inhibited whether the tumor products or CKS-17 conjugates were added early or late in the course of culture of stimulated EL4 cells. Inhibition by CKS-17 conjugates was selective in that IL-2 production was inhibited to a greater degree than general protein synthesis in EL4 cells, and general protein synthesis by fibroblasts was unaffected. Measurement of IL-2 mRNA suggested that inhibition of IL-2 production was mediated post-transcriptionally. Fractionation of six different tumor supernatants on Sephacryl S-300 revealed a single peak of activity with an apparent molecular mass of 18 kDa. Antibodies to CKS-17 conjugates neutralized the inhibitory effect of native tumor products on IL-2 production. Inhibition of IL-2 production, by factors related to p15E, provides a strategically effective means of subversion of host defenses by tumors, and abrogation of this inhibition by means of antibodies might promote host resistance to tumor growth.

Keywords: Apparent Molecular Mass, Tumor Product, Native Tumor, Protein p15E, General Protein Synthesis

References

  • 1.Aussel C, Didier M, Fehlmann M. Prostaglandin synthesis in human T cells: its partial inhibition by lectins and anti-CD3 antibodies as a possible step in T cell activation. J Immunol. 1987;138:3094–3099. [PubMed] [Google Scholar]
  • 2.Cianciolo GJ, Snyderman R. Neoplasia and mononuclear phagocyte function. In: Herberman RB, Friedman H, editors. The reticuloendothelial system, vol 5, Cancer. New York: Plenum Press; 1983. pp. 193–216. [Google Scholar]
  • 3.Cianciolo GJ, Hunter J, Silva J, Haskill JS, Snyderman R. Inhibitors of monocyte responses to chemotaxis are present in human cancerous effusions and react with monoclonal antibodies to the p15(E) structural protein of retroviruses. J Clin Invest. 1981;68:831–844. doi: 10.1172/JCI110338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Cianciolo GJ, Kipnis RJ, Snyderman R. Similarity between p15E of murine and feline leukaemia viruses and p21 of HTLV. Nature. 1984;311:515. doi: 10.1038/311515a0. [DOI] [PubMed] [Google Scholar]
  • 5.Cianciolo GH, Copelan TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral proteins. Science. 1985;230:453–455. doi: 10.1126/science.2996136. [DOI] [PubMed] [Google Scholar]
  • 6.Copelan EA, Rinehart JJ, Lewis M, Mathes L, Olsen R, Sagone A. The mechanism of retrovirus suppression of human T cell proliferation in vitro. J Immunol. 1983;131:2017–2020. [PubMed] [Google Scholar]
  • 7.Cornelius JG, Normann SJ. Isolation of a low molecular weight inhibitor of lymphocyte proliferation from tumorous ascites. J Immunol. 1988;141:2175–2180. [PubMed] [Google Scholar]
  • 8.Ebert EC, Roberts AI, O'Connell SM, Robertson FM, Nagase H. Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol. 1987;138:2161–2168. [PubMed] [Google Scholar]
  • 9.Efrat S, Zelig S, Yagen B, Kaemphfer R. Control of biologically active interleukin 2 messenger RNA formation in induced human lymphocytes. Proc Natl Acad Sci USA. 1984;81:2601–2605. doi: 10.1073/pnas.81.9.2601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Elliott L, Brooks W, Roszman T. Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J Natl Cancer Inst. 1987;78:919–922. [PubMed] [Google Scholar]
  • 11.Farram E, Nelson M, Nelson DS, Moon DK. Inhibition of cytokine production by a tumour cell product. Immunology. 1982;46:603–612. [PMC free article] [PubMed] [Google Scholar]
  • 12.Fontana A, Hengartner H, de Tribolet N, Weber E. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol. 1984;132:1837–1844. [PubMed] [Google Scholar]
  • 13.Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: Parameters of production and a quantitative microassay for activity. J Immunol. 1987;120:2027–2032. [PubMed] [Google Scholar]
  • 14.Gunning P, Ponte P, Okayama H, Engel J, Blau H, Kedes L. Isolation and characterization of full-length cDNA clones for human α-, β- and γ-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. Mol Cell Biol. 1983;3:787–795. doi: 10.1128/mcb.3.5.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hargett S, Wanebo HJ, Pace R, Katz D, Sando J, Cantrell R. Interleukin-2 production in head and neck cancer patients. Am J Surg. 1985;150:456–460. doi: 10.1016/0002-9610(85)90153-9. [DOI] [PubMed] [Google Scholar]
  • 16.Harrell RA, Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R. Suppression of the respiratory burst of human monocytes by a synthetic peptide homologous to envelope proteins of human and animal retroviruses. J Immunol. 1987;136:3517–3518. [PubMed] [Google Scholar]
  • 17.Harris DT, Cianciolo GJ, Snyderman R, Argov S, Koren HS. Inhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein, p15E. J Immunol. 1987;138:889–894. [PubMed] [Google Scholar]
  • 18.Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature. 1981;291:335–338. doi: 10.1038/291335a0. [DOI] [PubMed] [Google Scholar]
  • 19.Herman J, Kew MC, Rabson AR. Defective interleukin-1 production by natural killer cells of patients with cancer. Cancer Immunol Immunother. 1985;19:148–153. doi: 10.1007/BF00199724. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hersey P, Bindon C, Czerniecki M, Spurling A, Wass J, McCarthy WH. Inhibition of interleukin 2 production by factors released from tumor cells. J Immunol. 1983;131:2837–2842. [PubMed] [Google Scholar]
  • 21.Hessling JS, Miller SE, Levy NL. A direct comparison of procedures for the detection ofMycoplasma in tissue culture. J Immunol Methods. 1980;38:315–324. doi: 10.1016/0022-1759(80)90280-x. [DOI] [PubMed] [Google Scholar]
  • 22.Issekutz AC. Removal of Gram-negative endotoxin from solutions by affinity chromatography. J Immunol Methods. 1983;61:275–281. doi: 10.1016/0022-1759(83)90221-1. [DOI] [PubMed] [Google Scholar]
  • 23.Kamo I, Friedman H. Immunosuppression and the role of immunosuppressive factors in cancer. Adv Cancer Res. 1977;25:271–321. doi: 10.1016/s0065-230x(08)60636-3. [DOI] [PubMed] [Google Scholar]
  • 24.Kearney R, Nelson DS. Concomitant immunity to syngeneic methylcholanthrene-induced tumors in mice: Occurrence and specificity of concomitant immunity. Aust J Exp Biol Med Sci. 1973;51:723–735. doi: 10.1038/icb.1973.70. [DOI] [PubMed] [Google Scholar]
  • 25.Kleinerman ES, Lachman LB, Knowles RD, Snyderman R, Cianciolo GJ. A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1. J Immunol. 1987;139:2329–2337. [PubMed] [Google Scholar]
  • 26.Kurkinen M, Barlow DP, Jenkins JR, Hogan BLM. In vitro synthesis of laminin and enactin polypeptides. J Biol Chem. 1983;258:6543–6548. [PubMed] [Google Scholar]
  • 27.Kurnick JT, Ostberg L, Stegagno M, Kimura AK, Orn A, Sjoberg O. A rapid method for the separation of functional lymphoid cell populations of human and animal origins on PVP-silica (Percoll) density gradients. Scand J Immunol. 1979;10:563–573. doi: 10.1111/j.1365-3083.1979.tb01391.x. [DOI] [PubMed] [Google Scholar]
  • 28.Liotta LA, Vembu D, Kleinman HK, Martin GR, Boone C. Collagen required for proliferation of cultured connective tissue cells but not their transformed counterparts. Nature. 1978;272:622–624. doi: 10.1038/272622a0. [DOI] [PubMed] [Google Scholar]
  • 29.Loewenthal JW, Cerottini J-C, MacDonald HR. Interleukin 1-dependent induction of both interleukin 2 secretion and interleukin 2 receptor expression by thymoma cells. J Immunol. 1986;137:1226–1231. [PubMed] [Google Scholar]
  • 30.Maniatis T, Fritsch EF, Sambrook J. Molecular cloning. A laboratory manual. USA: Cold Spring Harbor Laboratory; 1982. [Google Scholar]
  • 31.Martin MA, Bryan T, McCutchan TF, Chan HW. Detection and cloning of murine leukemia virus-related sequences from African green monkey liver DNA. J Virol. 1981;39:835–844. doi: 10.1128/jvi.39.3.835-844.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Nelson DS, Nelson M. Evasion of host defences by tumours. Immunol Cell Biol. 1987;65:287–304. doi: 10.1038/icb.1987.33. [DOI] [PubMed] [Google Scholar]
  • 33.Nelson DS, Nelson M, Farram E, Inoue Y. Cancer and subversion of host defences. Aust J Exp Biol Med Sci. 1981;59:229–262. doi: 10.1038/icb.1981.18. [DOI] [PubMed] [Google Scholar]
  • 34.Nelson M, Nelson DS. Macrophages and resistance to tumours. I. Inhibition of delayed-type hypersensitivity reactions by tumour cells and by soluble products affecting macrophages. Immunology. 1978;34:277–290. [PMC free article] [PubMed] [Google Scholar]
  • 35.Nelson M, Nelson DS. Macrophages and resistance to tumors. IV. Influence of age on susceptibility of mice to antiinflammatory and antimacrophage effects of tumor cell products. J Natl Cancer Inst. 1980;65:781–789. doi: 10.1093/jnci/65.4.781. [DOI] [PubMed] [Google Scholar]
  • 36.Nelson M, Nelson DS. Inhibition of cell-mediated immunity by tumour cell products: depression of interleukin-2 production and responses to interleukin-2 by mouse spleen cells. Immunol Cell Biol. 1988;66:97–104. doi: 10.1038/icb.1988.13. [DOI] [PubMed] [Google Scholar]
  • 37.Nelson M, Nelson DS, Spradbrow PB, Kuchroo VK, Jennings PA, Cianciolo GJ, Snyderman R. Successful tumour immunotherapy: possible role of antibodies to antiinflammatory factors produced by neoplasms. Clin Exp Immunol. 1985;61:109–117. [PMC free article] [PubMed] [Google Scholar]
  • 38.Nelson M, Bremner JAG, Nelson DS. Tumour cell products inhibit both functional and immunoreactive interleukin 2 production by human blood lymphocytes. Br J Cancer. 1989;60:161–163. doi: 10.1038/bjc.1989.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Nelson M, Nelson DS, Cianciolo GJ, Snyderman R (1989) Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products. Cancer Immunol Immunother (in press) [DOI] [PMC free article] [PubMed]
  • 40.Ogasawara M, Cianciolo GJ, Snyderman R, Mitari M, Good RA, Day NK. Human gamma interferon production is inhibited by a synthetic peptide homologous to retroviral envelope protein. J Immunol. 1988;141:614–619. [PubMed] [Google Scholar]
  • 41.O'Neill RR, Khan AS, Hoggan MD, Hartley JW, Martin MA. Specific hybridization probes demonstrate fewer xenotropic than mink cell focus-forming murine leukemia virus env-related sequences in DNAs from inbred laboratory mice. J Virol. 1986;58:359–366. doi: 10.1128/jvi.58.2.359-366.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Putman JB, Jr, Roth JA. Identification and characterization of a tumor-derived immunosuppressive glycoprotein from murine melanoma K-1735. Cancer Immunol Immunother. 1985;19:90–100. doi: 10.1007/BF00199715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Rapp HJ, Churchill WH, Jr, Kronman BS, Rolley RT, Hammond WG, Borous T. Antigenicity of a new diethylnitrosamine-induced transplantable guinea pig hepatoma; pathology and formation of ascites variant. J Natl Cancer Inst. 1968;41:1–7. [PubMed] [Google Scholar]
  • 44.Ravikumar T, Rodrick M, Steele G, Jr, Marazzo J, O'Dwyer P, Dodson T, King V. Interleukin generation in experimental colon cancer of rats: effects of tumor growth and tumor therapy. J Natl Cancer Inst. 1985;74:893–898. [PubMed] [Google Scholar]
  • 45.Rosenberg SA. Immunotherapy of cancer using interleukin 2: current status and future protocols. Immunol Today. 1988;9:58–62. doi: 10.1016/0167-5699(88)91261-3. [DOI] [PubMed] [Google Scholar]
  • 46.Schantz SP, Shillitoe EJ, Brown B, Campbell B. Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst. 1986;77:869–875. [PubMed] [Google Scholar]
  • 47.Schmidt DM, Snyderman R. Retroviral protein p15E and tumorigenesis. Expression is neither required nor sufficient for tumor development. J Immunol. 1988;140:4035–4041. [PubMed] [Google Scholar]
  • 48.Shaw J, Meerovitch K, Bleackley RC, Paetkau V. Mechanisms regulating the level of IL-2 mRNA in T lymphocytes. J Immunol. 1988;140:2243–2248. [PubMed] [Google Scholar]
  • 49.Smith KA. Interleukin-2: inception, impact and implications. Science. 1988;240:1169–1176. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  • 50.Snyderman R, Cianciolo GJ. Immunosuppressive activity of the retroviral envelope protein p15E and its possible relationship to neoplasia. Immunol Today. 1984;5:240–244. doi: 10.1016/0167-5699(84)90097-5. [DOI] [PubMed] [Google Scholar]
  • 51.Steele PE, Martin MA, Rabson AB, Bryan T, O'Brien SJ. Amplification and chromosomal dispersion of human endogenous retroviral sequences. J Virol. 1986;59:545–550. doi: 10.1128/jvi.59.3.545-550.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Thomas PD. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci USA. 1980;77:5201–5205. doi: 10.1073/pnas.77.9.5201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Wahl SM, McCartney-Francis M, Hunt DA, Smith PD, Wahl LM, Katona IM. Monocyte interleukin 2 receptor gene expression and interleukin 2 augmentation of microbicidal activity. J Immunol. 1987;139:1342–1347. [PubMed] [Google Scholar]
  • 54.Wanebo HJ, Pace R, Hargett S, Katz D, Sando J. Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer. 1986;57:656–662. doi: 10.1002/1097-0142(19860201)57:3<656::aid-cncr2820570343>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  • 55.Wang JM, Cianciolo GJ, Snyderman R, Mantovani A. Coexistance of a chemotactic factor and a retroviral p15E-related chemotaxis inhibitor in human tumor cell culture supernatants. J Immunol. 1986;137:2726–2732. [PubMed] [Google Scholar]
  • 56.Weiss A, Shields R, Newton M, Manger B, Imboden T. Ligand receptor interactions required for commitment to the activation of the interleukin 2 gene. J Immunol. 1987;138:2169–2176. [PubMed] [Google Scholar]
  • 57.Werkmeister J, Zaunders J, McCarthy W, Hersey P. Characterization of an inhibitor of cell division released in cell cultures. Clin Exp Immunol. 1980;41:487–496. [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES